Home › Funds › Siren, L.L.C. › ARWR
Siren, L.L.C. position in ARWR
Arrowhead Pharmaceuticals, Inc. · Health Care
Siren, L.L.C. reported holding 2,290,476 shares of ARWR (Arrowhead Pharmaceuticals, Inc.) in its Q3 2026 13F filing — a position valued at US$149.9M, representing 3.56% of its reported portfolio and ranking #8 among its reported holdings. Siren, L.L.C. has disclosed ARWR holdings in 9 of the last 9 reported quarters, going back to Q3 2024.
Last updated: 2026-11-12 · Source: SEC EDGAR Form 13F-HR
How Siren, L.L.C.'s ARWR position evolved
Siren, L.L.C. first disclosed a stake in ARWR in Q3 2024 at 2,458,778 shares (US$47.6M). The position peaked in Q3 2026 at 2,290,476 shares, worth US$149.9M. Across 9 filings, Siren, L.L.C. increased the stake 4 time(s), trimmed it 2 time(s) and left it unchanged 2 time(s). The most recent filing (Q3 2026) shows 2,290,476 shares valued at US$149.9M — an increase of 575,000 shares quarter over quarter.. Notable position changes include a 44% trim in Q4 2025 (shares fell 6% over the following quarter), a 34% increase in Q3 2026 (shares fell 25% over the following quarter).
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q3 2024 | 2.46M | $47.63M | New |
| Q4 2024 | 2.90M | $54.55M | Add |
| Q1 2025 | 2.67M | $34.01M | Reduce |
| Q2 2025 | 2.67M | $42.18M | Hold |
| Q3 2025 | 2.67M | $92.08M | Hold |
| Q4 2025 | 1.50M | $99.62M | Reduce |
| Q1 2026 | 1.62M | $101.29M | Add |
| Q2 2026 | 1.72M | $139.83M | Add |
| Q3 2026 | 2.29M | $149.91M | Add |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About ARWR and 13F data
ARWR (Arrowhead Pharmaceuticals, Inc.) is a Health Care company. 50 other funds we track also report a position in ARWR — the largest reported positions include Avoro Capital Advisors LLC (US$925.6M), FRED ALGER MANAGEMENT, LLC (US$269.1M), BAKER BROS. ADVISORS LP (US$162.4M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding ARWR
- Avoro Capital Advisors LLC 11.36M sh · $925.59M · Q2 2026
- FRED ALGER MANAGEMENT, LLC 3.30M sh · $269.14M · Q2 2026
- BAKER BROS. ADVISORS LP 1.99M sh · $162.43M · Q2 2026
- Vestal Point Capital, LP 1.57M sh · $128.38M · Q2 2026
- DEERFIELD MANAGEMENT COMPANY, L.P. 1.39M sh · $113.22M · Q2 2026
- DRIEHAUS CAPITAL MANAGEMENT LLC 1.35M sh · $110.08M · Q2 2026
- Hood River Capital Management LLC 1.12M sh · $91.35M · Q2 2026
- SUMMIT PARTNERS PUBLIC ASSET MANAGEMENT, LLC 830.25K sh · $67.67M · Q2 2026
- Western Financial Corp/CA 820.24K sh · $53.68M · Q3 2026
- READYSTATE ASSET MANAGEMENT LP 25.00M sh · $29.94M · Q2 2026
- MACKAY SHIELDS LLC 27.19M sh · $27.84M · Q3 2026
FAQ
How long has Siren, L.L.C. held ARWR?
Siren, L.L.C. has disclosed ARWR holdings in 9 of the last 9 reported quarters, going back to Q3 2024.
What is Siren, L.L.C.'s current position in ARWR?
As of Q3 2026, Siren, L.L.C. holds 2.29M shares of ARWR (Arrowhead Pharmaceuticals, Inc.), valued at $149.91M, representing 3.56% of its reported portfolio and ranking #8.
Has Siren, L.L.C. been buying or selling ARWR?
In the latest 13F filing (Q3 2026), Siren, L.L.C. increased its position in ARWR. The position peaked in Q3 2026 at 2.29M shares.
Which other funds hold ARWR?
Other major institutional holders of ARWR include Avoro Capital Advisors LLC, FRED ALGER MANAGEMENT, LLC, BAKER BROS. ADVISORS LP, among 50 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.